proactive
Management
Apr 23, 2024

Leonid Gokhman, PharmD, manager of pharmacy business operations at Harris Health System, takes a proactive approach to running his operation, rather than being reactive. He encourages his pharmacy, nursing, IT and revenue cycle peers to adopt this mindset.

“If you’re reactive, you’re creating so many other issues — not only for yourself, but for multiple teams,” Dr. Gokhman says. “If you're able to put things in place that prevent issues from happening in the first place, you drastically cut down on a lot of clutter, errors and unnecessary work.”

Part of taking a proactive approach means working directly with the frontline staff not only on project development and implementation, but maintenance as well. Staying within the pharmacy walls and only working with your team means you’re not getting the bigger picture of how the hospital system operates, he says. 

Plus, when major departmental initiatives are carried out in silos, crucial components may be overlooked. This oversight could result in either beneficial or detrimental downstream effects for other departments.

Five years ago, he was asked to participate in the hospital system’s vaccine redesign project. When he first started the project, the error rate was almost 50%. (Yes, you read that right. 5-0.)

“If you have errors in your clinical documentation and on your charges, you will not get paid or get paid inappropriately,” Dr. Gokhman says. “As I was digging through the system build and working with nursing leadership — it became clear to me that the system build was way too complicated. Our providers had five different workflows, requiring them to memorize numerous charge codes to manually post administration charges and contend with confusing order names. This diverted their attention away from direct patient care.”

Five workflows were four too many. His first step was to consolidate multiple provider and nursing workflows into one. Next, vaccine order names were updated according to ISMP (Institute for Safe Medication Practices) and Epic guidelines. Finally, a system build was implemented to automatically post vaccine and vaccine administration charges based on the documentation for each vaccine.

“Keep it simple,” Dr. Gokhman says. “When frontline staff are presented with too many options, they are prone to choosing incorrectly or resorting to workarounds. These workarounds might seem beneficial, but on the frontend, they lead to order entry and documentation errors. This causes multiple coding, billing and reimbursement issues on the backend.”

By simplifying and automating the workflow, they’ve drastically cut down the number of errors.  Recently, a third-party audit revealed a 100% vaccine billing compliance rate, surpassing the industry standard of 95%.

VPL TrajectRx
Apr 15, 2024

VPL TrajectRx empowers outpatient pharmacies by giving them the cloud-based shipping, tracking and compliance solution they need to build cost-conscious, stronger, and smarter last-mile operations. Created for pharmacists by pharmacists, our clinically minded platform gets prescriptions out the door, tracks and traces them to their destination, communicates shipping updates to patients and staff, and compiles necessary reporting for proof of delivery.

Duke University
Mar 29, 2024

i-Health, Inc. is proud to support clinical research and advance scientific knowledge around probiotics, including a
recent investigator-initiated trial conducted by clinician researchers at Duke University using Culturelle® probiotics.

i-Health, Inc.
AI in healthcare
Mar 26, 2024

Drug shortages are becoming a pervasive global issue.  In the United States alone, there were 309 active drug shortages at the end of the second quarter of 2023 — the most in nearly a decade and close to the all-time high of 320 shortages, according to a report by the American Society of Health-System Pharmacists. Causes of these shortages are varied and complex, ranging from manufacturing and quality issues to unexpected demand surges, posing significant risks to public health.

Partner Voice
Apr 23, 2024

Pharmacy Angle CEO David Mason and Lani Bertrand, RPh, senior director of clinical consulting at Omnicell discuss the growth, challenges and the prospect of modern solutions to staffing, logistics and service in Pharmacy.

Educational
Mar 27, 2024

Moderator Amir Emamifar, who's career spans more than 30 years a clinical pharmacist, leads a panel discussion on the topic "Bridging Policy to Practice: Navigating the 340B Program's Landscape and Embracing Opportunities featuring the following panelist: 

Patti Hawkins, PharmD - Interim Administrator for Oncology Services and serves on the clinical faculty at the Union University School of Pharmacy

Christopher Hatwig, MS, RPh, FASHP - President at Apexus

Executive Insights
Mar 20, 2024

In the wake of the Change Healthcare cyber attack that caused major disruption across the industry, Ken Perez, Healthcare IT, marketing and policy consultant and former Vice President of Healthcare Policy and Government Affairs for Omnicell, Inc. had the opportunity recently visit wit ScriptPro CEO, Mike Coughlin to learn what was affected, what work arounds were put in place, and what lessons were learned. 

Webinars, Partner Voice
Mar 18, 2024

VPL TrajectRx empowers outpatient pharmacies by giving them the cloud-based shipping, tracking and compliance solution they need to build cost-conscious, stronger, and smarter last-mile operations. Created for pharmacists by pharmacists, our clinically minded platform gets prescriptions out the door, tracks and traces them to their destination, communicates shipping updates to patients and staff, and compiles necessary reporting for proof of delivery.

Healthcare Ruling Signature
Apr 22, 2024

WASHINGTON, DC — The Department of Health and Human Services (HHS) issued a final rule revising the administrative dispute resolution (ADR) process under the 340B program. This final rule will apply to all drug manufacturers and covered entities that participate in the 340B Program, addressing the requirements and procedures for the 340B Program’s administrative dispute resolution (ADR) process.

According to the American Hospital Association, the ADR process allows all 340B-covered entities — regardless of the size of the organization or monetary value of the claim — to address claims at dispute with drug companies.

"The final rule contains several important process improvements, including a clear timeline for when ADR decisions must be made and an opportunity for reconsideration when parties are dissatisfied with the initial ADR decision," AHA General Counsel Chad Golder said. "The AHA is particularly pleased that the final rule makes clear that an overcharge claim includes instances where a drug company has limited a hospital's ability to purchase 340B drugs at or below the 340B ceiling price. This rule will help hold drug companies accountable for their rampant abuses of the 340B program and the patients it serves."

“340B Health is pleased that HRSA’s (Health Resources & Services Administration) final rule aligns with several of our recommendations for revisions and clarifications to the agency’s proposed rule," Maureen Testoni, president and CEO of 340B Health, said."We are particularly encouraged by the final rule clarifying that a covered entity’s ADR claims can include accusations that a drug company has limited the ability to purchase drugs at or below the 340B ceiling price and removing a proposed amendment to block ADR consideration of a claim similar to an issue pending in federal court. HRSA’s removal of potential conflicts of interest and unnecessary legal barriers are additional positive steps that will simplify and streamline the dispute resolution process for the benefit of all participants.”

This rule, which may be viewed in full here, will come into effect on June 18, 2024. 

Takeda’s ENTYVIO® (vedolizumab)
Apr 19, 2024

CAMBRIDGE, MA – Takeda (NYSE:TAK) announced that the U.S.

Eli Lilly drug tirzepatide, marketed as Zepbound for weight management
Apr 17, 2024

INDIANAPOLIS, IN – Eli Lilly and Company (NYSE: LLY) announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies.

Hospital Pharmaceuticals
Apr 15, 2024

LOUISVILLE, KY — ScionHealth announced today they will begin purchasing certain bulk drugs from Mark Cuban’s Cost Plus Drug Company (“Cost Plus Drugs”) and delivered to Safecor Health’s SafecorLogics program. The integrated approach, combining the expertise of three organizations, will enable ScionHealth to deliver exceptional value to patients while ensuring the sustainability of its healthcare delivery model.